 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
12 News |  |
- ||||| phosphatidylcholine CR (LT‑02) / Lipid Therap, Nestle, Dr Falk
Trial completion: Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (clinicaltrials.gov) - Jan 27, 2020
P3, N=150, Completed, Sponsor: Dr. Falk Pharma GmbH
Active, not recruiting --> Completed
- ||||| phosphatidylcholine CR (LT‑02) / Lipid Therap, Nestle, Dr Falk
Enrollment closed, Enrollment change: Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (clinicaltrials.gov) - Apr 6, 2018
P3, N=150, Active, not recruiting, Sponsor: Dr. Falk Pharma GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=400 --> 150
- phosphatidylcholine CR (LT?02) / Lipid Therap, Nestle, Dr Falk
Enrollment change, Trial termination: PROTECT-3: A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC) (clinicaltrials.gov) - Jun 15, 2017
P3, N=25, Terminated, Sponsor: Prometheus Laboratories
Recruiting --> Active, not recruiting | N=400 --> 150 N=510 --> 25 | Recruiting --> Terminated; LT-02 did not appear to help induce remission of UC
- | phosphatidylcholine CR (LT?02) / Lipid Therap, Nestle, Dr Falk
Enrollment change, Trial termination: Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (clinicaltrials.gov) - Feb 9, 2017
P3, N=468, Terminated, Sponsor: Dr. Falk Pharma GmbH
N=510 --> 25 | Recruiting --> Terminated; LT-02 did not appear to help induce remission of UC N=762 --> 468 | Recruiting --> Terminated; IDMC recommendation
- |||||||||| phosphatidylcholine CR (LT?02) / Lipid Therap, Nestle, Dr Falk
New P3 trial: PROTECT-3: A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC) (clinicaltrials.gov) - Jul 29, 2016
P3, N=510, Recruiting, Sponsor: Prometheus Laboratories
- |||||||||| phosphatidylcholine CR (LT‑02) / Lipid Therap, Nestle, Dr Falk
New P3 trial: Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) (clinicaltrials.gov) - Oct 31, 2014
P3, N=400, Recruiting, Sponsor: Dr. Falk Pharma GmbH
- |||||| phosphatidylcholine CR (LT?02) / Lipid Therap, Nestle, Dr Falk
Enrollment open, Trial primary completion date: Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (clinicaltrials.gov) - Oct 30, 2014
P3, N=762, Recruiting, Sponsor: Dr. Falk Pharma GmbH
N=762 --> 468 | Recruiting --> Terminated; IDMC recommendation Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Dec 2016
- |||||||||| phosphatidylcholine CR (LT?02) / Lipid Therap, Nestle, Dr Falk
New P3 trial: Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis (clinicaltrials.gov) - May 18, 2014
P3, N=762, Not yet recruiting, Sponsor: Dr. Falk Pharma GmbH